VRTX – Only one week before the Telaprevir PROVE-1/2 data are to be presented at AASLD, VRTX today disclosed for the first time the existence of a follow-on HCV protease inhibitor. Does anyone think the timing of this disclosure is significant?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”